CRISPR THERAPEUTICS AG Capital Expenditures
CRISPR THERAPEUTICS AG (CRSP) reported Capital Expenditures of $1.15 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-03
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $648.00K, a 453.85% increase year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $504.00K, a 144.66% increase year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $517.00K, a 103.54% increase year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $74.00K, a 66.21% decline year-over-year.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for fiscal 2025 was $914.00K, a 51.92% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for fiscal 2024 was $1.90M, a 79.93% decline from fiscal 2023.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for fiscal 2023 was $9.47M, a 74.53% decline from fiscal 2022.
- CRISPR THERAPEUTICS AG payments to acquire property, plant, and equipment for fiscal 2022 was $37.19M, a 54.49% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $648.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.15M 10-Q · filed 2026-08-03 | $1.67M derived: sum of 3 quarters · filed 2026-08-03 | $1.74M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $504.00K 10-Q · filed 2026-05-04 | $1.02M derived: sum of 2 quarters · filed 2026-05-04 | $1.09M derived: sum of 3 quarters · filed 2026-05-04 | $1.21M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $591.00K derived: sum of 2 quarters · filed 2026-02-12 | $708.00K derived: sum of 3 quarters · filed 2026-08-03 | $914.00K 10-K · filed 2026-02-12 |
| 2025-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $191.00K derived: sum of 2 quarters · filed 2026-08-03 | $397.00K 10-Q · filed 2025-11-10 | $651.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $323.00K 10-Q · filed 2026-08-03 | $577.00K derived: sum of 3 quarters · filed 2026-08-03 | $796.00K derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $206.00K 10-Q · filed 2026-05-04 | $460.00K derived: sum of 2 quarters · filed 2026-05-04 | $679.00K derived: sum of 3 quarters · filed 2026-05-04 | $1.39M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $254.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $473.00K derived: sum of 2 quarters · filed 2026-02-12 | $1.18M derived: sum of 3 quarters · filed 2026-02-12 | $1.90M 10-K · filed 2026-02-12 |
| 2024-09-30 | $219.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $926.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.65M 10-Q · filed 2025-11-10 | $2.38M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-06-30 | $707.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $1.43M 10-Q · filed 2025-08-04 | $2.17M derived: sum of 3 quarters · filed 2026-02-12 | $4.28M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-03-31 | $721.00K 10-Q · filed 2025-05-06 | $1.46M derived: sum of 2 quarters · filed 2026-02-12 | $3.58M derived: sum of 3 quarters · filed 2026-02-12 | $7.13M derived: sum of 4 quarters · filed 2026-02-12 |
| 2023-12-31 | $738.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $2.86M derived: sum of 2 quarters · filed 2026-02-12 | $6.41M derived: sum of 3 quarters · filed 2026-02-12 | $9.47M 10-K · filed 2026-02-12 |
| 2023-09-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $5.67M derived: sum of 2 quarters · filed 2024-11-05 | $8.73M 10-Q · filed 2024-11-05 | $14.92M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $3.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $6.61M 10-Q · filed 2024-08-05 | $12.80M derived: sum of 3 quarters · filed 2025-02-11 | $18.82M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $3.06M 10-Q · filed 2024-05-08 | $9.25M derived: sum of 2 quarters · filed 2025-02-11 | $15.27M derived: sum of 3 quarters · filed 2025-02-11 | $24.90M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $6.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $12.21M derived: sum of 2 quarters · filed 2025-02-11 | $21.84M derived: sum of 3 quarters · filed 2025-02-11 | $37.19M 10-K · filed 2025-02-11 |
| 2022-09-30 | $6.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $15.65M derived: sum of 2 quarters · filed 2023-11-06 | $31.00M 10-Q · filed 2023-11-06 | $40.18M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-06-30 | $9.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $24.98M 10-Q · filed 2023-08-07 | $34.16M derived: sum of 3 quarters · filed 2024-02-21 | $71.21M derived: sum of 4 quarters · filed 2024-02-21 |
| 2022-03-31 | $15.35M 10-Q · filed 2022-05-09 | $24.53M derived: sum of 2 quarters · filed 2024-02-21 | $61.58M derived: sum of 3 quarters · filed 2024-02-21 | $90.03M derived: sum of 4 quarters · filed 2024-02-21 |
| 2021-12-31 | $9.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $46.23M derived: sum of 2 quarters · filed 2024-02-21 | $74.68M derived: sum of 3 quarters · filed 2024-02-21 | $81.70M 10-K · filed 2024-02-21 |
| 2021-09-30 | $37.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $65.50M derived: sum of 2 quarters · filed 2022-11-01 | $72.52M 10-Q · filed 2022-11-01 | $78.76M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | $28.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $35.47M 10-Q · filed 2022-08-08 | $41.71M derived: sum of 3 quarters · filed 2023-02-21 | $47.23M derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-03-31 | $7.02M 10-Q · filed 2022-05-09 | $13.26M derived: sum of 2 quarters · filed 2023-02-21 | $18.79M derived: sum of 3 quarters · filed 2023-02-21 | $22.39M derived: sum of 4 quarters · filed 2023-02-21 |
| 2020-12-31 | $6.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-21 | $11.76M derived: sum of 2 quarters · filed 2023-02-21 | $15.37M derived: sum of 3 quarters · filed 2023-02-21 | $18.36M 10-K · filed 2023-02-21 |
| 2020-09-30 | $5.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $9.13M derived: sum of 2 quarters · filed 2021-11-03 | $12.12M 10-Q · filed 2021-11-03 | $13.07M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $3.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-29 | $6.60M 10-Q · filed 2021-07-29 | $7.55M derived: sum of 3 quarters · filed 2022-02-15 | $10.01M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $2.99M 10-Q · filed 2021-04-27 | $3.94M derived: sum of 2 quarters · filed 2022-02-15 | $6.40M derived: sum of 3 quarters · filed 2022-02-15 | $8.58M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $952.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $3.41M derived: sum of 2 quarters · filed 2022-02-15 | $5.59M derived: sum of 3 quarters · filed 2022-02-15 | $6.68M 10-K · filed 2022-02-15 |
| 2019-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $4.63M derived: sum of 2 quarters · filed 2020-10-28 | $5.73M 10-Q · filed 2020-10-28 | $6.73M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-06-30 | $2.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-27 | $3.27M 10-Q · filed 2020-07-27 | $4.27M derived: sum of 3 quarters · filed 2021-02-16 | $4.97M derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-03-31 | $1.10M 10-Q · filed 2020-04-28 | $2.10M derived: sum of 2 quarters · filed 2021-02-16 | $2.79M derived: sum of 3 quarters · filed 2021-02-16 | $3.31M derived: sum of 4 quarters · filed 2021-02-16 |
| 2018-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $1.70M derived: sum of 2 quarters · filed 2021-02-16 | $2.22M derived: sum of 3 quarters · filed 2021-02-16 | $2.77M 10-K · filed 2021-02-16 |
| 2018-09-30 | $695.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-28 | $1.22M derived: sum of 2 quarters · filed 2019-10-28 | $1.77M 10-Q · filed 2019-10-28 | $1.98M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-06-30 | $523.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $1.08M 10-Q · filed 2019-07-29 | $1.28M derived: sum of 3 quarters · filed 2020-02-12 | $4.28M derived: sum of 4 quarters · filed 2020-02-12 |
| 2018-03-31 | $555.00K 10-Q · filed 2019-04-29 | $760.00K derived: sum of 2 quarters · filed 2020-02-12 | $3.75M derived: sum of 3 quarters · filed 2020-02-12 | $5.08M derived: sum of 4 quarters · filed 2020-02-12 |
| 2017-12-31 | $205.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-12 | $3.20M derived: sum of 2 quarters · filed 2020-02-12 | $4.53M derived: sum of 3 quarters · filed 2020-02-12 | $7.81M 10-K · filed 2020-02-12 |
| 2017-09-30 | $2.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $4.32M derived: sum of 2 quarters · filed 2018-11-07 | $7.61M 10-Q · filed 2018-11-07 | $7.84M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $4.62M 10-Q · filed 2018-08-07 | $4.84M derived: sum of 3 quarters · filed 2019-02-25 | $6.35M derived: sum of 4 quarters · filed 2019-02-25 |
| 2017-03-31 | $3.29M 10-Q · filed 2018-05-08 | $3.51M derived: sum of 2 quarters · filed 2019-02-25 | $5.02M derived: sum of 3 quarters · filed 2019-02-25 | $6.07M derived: sum of 4 quarters · filed 2019-02-25 |
| 2016-12-31 | $228.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $1.74M derived: sum of 2 quarters · filed 2019-02-25 | $2.78M derived: sum of 3 quarters · filed 2019-02-25 | $3.02M 10-K · filed 2019-02-25 |
| 2016-09-30 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.56M derived: sum of 2 quarters · filed 2017-11-08 | $2.79M 10-Q · filed 2017-11-08 | $3.29M derived: sum of 4 quarters · filed 2018-03-08 |
| 2016-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | $1.28M 10-Q · filed 2017-08-10 | $1.78M derived: sum of 3 quarters · filed 2018-03-08 | |
| 2016-03-31 | $232.00K 10-Q · filed 2017-05-11 | $735.00K derived: sum of 2 quarters · filed 2018-03-08 | ||
| 2015-12-31 | $503.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $1.15M 10-K · filed 2018-03-08 | ||
| 2015-09-30 | $651.00K 10-Q · filed 2016-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |